Adalimumab biosimilar - Biocad

Drug Profile

Adalimumab biosimilar - Biocad

Alternative Names: BCD 057

Latest Information Update: 12 Apr 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Biocad
  • Class Anti-inflammatories; Anti-TNF monoclonal antibodies; Antipsoriatics; Antirheumatics
  • Mechanism of Action Immunomodulators; Tumour necrosis factor alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Plaque psoriasis; Rheumatoid arthritis

Most Recent Events

  • 01 Dec 2016 Biocad initiates enrolment in the CALYPSO phase III trial for Plaque psoriasis in Russia (NCT02762955)
  • 19 Jul 2016 Phase-III clinical trials in Plaque psoriasis in Russia (SC) (Biocad pipeline, July 2016)
  • 19 Jul 2016 Phase-III clinical trials in Rheumatoid arthritis in Russia (SC) (Biocad pipeline, July 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top